Morepen Labs Secures ₹30 Crore Working Capital Loan from KEB Hana Bank
Morepen Laboratories Limited secured an unsecured working capital term loan of ₹30 crore from KEB Hana Bank. The loan has a 3-year tenure with a 6-month moratorium and a 7.30% annual interest rate. Mr. Sushil Suri provided a personal guarantee.
The infusion of ₹30 crore in working capital is substantial and will aid in the company's operations, but it is a debt facility, and the overall financial health depends on repayment capabilities.
The company has successfully secured a significant working capital loan, which is positive for its operational liquidity and financial flexibility.
Morepen Laboratories Limited has secured a significant working capital term loan facility amounting to ₹30 crore from KEB Hana Bank. The Finance Committee of the Board of Directors approved this unsecured loan on March 10, 2026, during a meeting that commenced at 6:00 p.m. and concluded at 6:45 p.m.
The loan agreement, executed on March 10, 2026, has a tenure of 3 years. The repayment structure includes a 6-month moratorium followed by five half-yearly equal installments. The interest rate is set at the prevailing repo rate plus 2.05% per annum, with the current effective rate being 7.30% per annum.
This facility is supported by a personal guarantee from Mr. Sushil Suri, Promoter, Chairman & Managing Director of Morepen Laboratories Limited. As of March 10, 2026, the company had no outstanding loans from KEB Hana Bank, though its total outstanding loans from other sources amounted to ₹164.62 crore (excluding vehicle loans).
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.